Novavax Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$81.7M
Doctors Paid
346
Transactions
6,792
2024 Total
$30.4M
Payment Breakdown by Category
Research$81.3M (99.5%)
Consulting$300,752 (0.4%)
Travel$20,622 (0.0%)
Food & Beverage$12,056 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $81.3M | 6,303 | 99.5% |
| Consulting Fee | $300,752 | 52 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $51,229 | 13 | 0.1% |
| Travel and Lodging | $20,622 | 44 | 0.0% |
| Food and Beverage | $12,056 | 380 | 0.0% |
Payments by Type
Research
$81.3M
6,303 transactions
General
$384,659
489 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | $15.9M | 5 | 1,137 |
| Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to younger than 12 Years | $12.4M | 1 | 627 |
| A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | $10.3M | 1 | 1,584 |
| A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | $9.7M | 27 | 1,049 |
| A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in Children 6 Months to < 12 Years of Age | $7.7M | 3 | 347 |
| A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines | $3.9M | 13 | 505 |
| A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naïve Participants | $2.9M | 0 | 332 |
| 2019nCoV-301 A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults younger or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to under 18 Years) at Risk for SARS-CoV-2 | $2.9M | 0 | 2 |
| Study of Health care workers and First Responders Investigating Effects of Systemic and Local reactogenicity of COVID-19 Vaccine Doses in Utah (SHIELD Utah) | $2.8M | 0 | 4 |
| A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naive Participants | $2.2M | 0 | 135 |
| BEEHIVE: Booster Epidemiological Evaluation of Health, Illness and Vaccine Efficacy | $2.0M | 0 | 4 |
| A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) | $2.0M | 0 | 90 |
| Booster Epidemiological Evaluation of Health, Illness and Vaccine Efficacy (BEEHIVE) Study | $997,438 | 0 | 3 |
| Booster Epidemiological Evaluation of Health Illness and Vaccine Efficacy (BEEHIVE) Study | $900,000 | 0 | 1 |
| A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults younger than 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) at Risk for SARS-CoV-2 | $871,516 | 0 | 52 |
| Longitudinal Follow-up of SARS-CoV-2 (COVID-19) Immunity in Immunocompromised Populations in Belgium (COVICO) in Nursing Home Residents and Staff During the Winter Season 2022-2023 | $856,377 | 0 | 314 |
| Novavax Vaccine Real World Trial | $636,219 | 0 | 2 |
| 2019nCoV-503 Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to less than 12 Years | $597,437 | 0 | 2 |
| A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix[1]M Adjuvant in Healthy Subjects study | $429,188 | 0 | 45 |
| 2019nCoV-311 Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines | $399,344 | 0 | 2 |
| A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years with a Pediatric Expansion in Adolescents (12 to younger than 18 Years) | $275,633 | 1 | 31 |
| Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines | $224,026 | 0 | 5 |
| Booster Epidemiological Evaluation of Health, Illness and Vaccine Efficacy | $214,884 | 0 | 1 |
| 2019nCoV-307 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults | $141,653 | 0 | 2 |
| Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations (ARMOR-COVID) | $140,562 | 0 | 1 |
| Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults | $55,814 | 0 | 1 |
| A Randomized, Observer-Blinded, Phase 3 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults | $37,814 | 0 | 24 |
| A 2-PART, PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A SARS-CoV-2 RECOMBINANT SPIKE PROTEIN NANOPARTICLE VACCINE (SARS-CoV-2 rS) WITH OR WITHOUT MATRIX-M™ADJUVANT IN HEALTHY SUBJECTS | $250.00 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Infectious Disease | $259,917 | 6 | $43,319 |
| Pediatrics | $153,958 | 25 | $6,158 |
| Family | $28,552 | 52 | $549.09 |
| Internal Medicine | $20,842 | 60 | $347.36 |
| Pediatric Infectious Diseases | $19,386 | 8 | $2,423 |
| Family Medicine | $19,326 | 68 | $284.21 |
| Physician Assistant | $14,028 | 19 | $738.30 |
| Geriatric Medicine | $13,560 | 3 | $4,520 |
| Pediatric Critical Care Medicine | $9,725 | 2 | $4,863 |
| Surgery | $6,832 | 1 | $6,832 |
| Nurse Practitioner | $6,181 | 12 | $515.05 |
| Contractor | $5,613 | 1 | $5,613 |
| Emergency Medicine | $4,481 | 7 | $640.20 |
| Medical Toxicology | $4,244 | 1 | $4,244 |
| Specialist | $4,242 | 3 | $1,414 |
| Obstetrics | $2,884 | 2 | $1,442 |
| Otolaryngology | $2,651 | 2 | $1,325 |
| Ophthalmology | $2,600 | 1 | $2,600 |
| Pulmonary Disease | $1,964 | 3 | $654.65 |
| Adolescent Medicine | $1,609 | 3 | $536.34 |
| Adult Health | $1,538 | 9 | $170.87 |
| Critical Care Medicine | $1,354 | 2 | $676.97 |
| General Practice | $1,313 | 11 | $119.38 |
| Student in an Organized Health Care Education/Training Program | $321.84 | 10 | $32.18 |
| Medical | $277.29 | 7 | $39.61 |
| Cardiovascular Disease | $94.89 | 2 | $47.45 |
| Primary Care | $61.52 | 2 | $30.76 |
| Registered Nurse | $57.58 | 2 | $28.79 |
| Hospitalist | $52.73 | 2 | $26.37 |
| Medical-Surgical | $47.64 | 2 | $23.82 |
| Athletic Trainer | $38.62 | 1 | $38.62 |
| Psychiatry | $27.10 | 1 | $27.10 |
| Legal Medicine | $26.28 | 1 | $26.28 |
| Advanced Practice Midwife | $25.57 | 1 | $25.57 |
| Podiatrist | $24.05 | 1 | $24.05 |
| Pediatric Pulmonology | $21.89 | 1 | $21.89 |
| Psychiatric/Mental Health | $20.79 | 1 | $20.79 |
| Behavior Analyst | $20.78 | 1 | $20.78 |
| Emergency | $19.89 | 1 | $19.89 |
| Acute Care | $19.68 | 1 | $19.68 |
| Nephrology | $18.72 | 1 | $18.72 |
| Obstetrics & Gynecology | $15.73 | 1 | $15.73 |
| Sports Medicine | $14.52 | 1 | $14.52 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Robert Redfield, M.d, M.D | Infectious Disease | Baltimore, MD | $140,000 | $0 |
| Dr. Shelly Senders, Md, MD | Pediatrics | South Euclid, OH | $102,110 | $0 |
| Philip Krause, M.d, M.D | Infectious Disease | Potomac, MD | $101,333 | $0 |
| Unknown Provider | — | — | $29,388 | $0 |
| Jennifer Thompson, M.d, M.D | Pediatrics | Pensacola, FL | $13,913 | $0 |
| Stanley Deresinski, Md, MD | Infectious Disease | Palo Alto, CA | $13,738 | $0 |
| Todd Wolynn, Md, MD | Pediatrics | Pittsburgh, PA | $13,573 | $0 |
| Stefan Gravenstein, Md, MD | Geriatric Medicine | Providence, RI | $13,512 | $0 |
| Dr. Robert Enelow, M.d, M.D | Internal Medicine | Washington, DC | $11,850 | $0 |
| Dr. Michael Simon, M.d, M.D | Pediatrics | Nicholasville, KY | $11,196 | $0 |
| Zaifang Yu, Crnp, CRNP | Family | Philadelphia, PA | $10,300 | $0 |
| Joseph Domachowske, Md, MD | Pediatric Infectious Diseases | Syracuse, NY | $7,206 | $0 |
| Mrs. Tracey Piparo, Pa-C, PA-C | Physician Assistant | New Brunswick, NJ | $6,922 | $0 |
| Dr. Matthew Cunningham-Hill, M.d, M.D | Surgery | Morgantown, WV | $6,832 | $0 |
| Wendy Wright, Arnp, ARNP | Family | Amherst, NH | $6,585 | $0 |
| Ruth Carrico, Rn, Msn, Phd, RN, MSN, PHD | Family | Louisville, KY | $6,195 | $0 |
| Letha Joseph | Nurse Practitioner | Morrisville, NC | $5,944 | $0 |
| Dr. Donald Middleton, Md, MD | Pediatrics | Pittsburgh, PA | $5,889 | $0 |
| Dr. Lee Polikoff, M.d, M.D | Pediatric Critical Care Medicine | Providence, RI | $5,725 | $0 |
| Dr. Jaime Fergie, M.d, M.D | Pediatric Infectious Diseases | Corpus Christi, TX | $5,721 | $0 |
| Peter Patriarca, M.d, M.D | Contractor | Bethesda, MD | $5,613 | $0 |
| Rachel La Costa, Pa-C, PA-C | Physician Assistant | San Francisco, CA | $4,843 | $0 |
| Dr. Angela Branche, Md, MD | Infectious Disease | Rochester, NY | $4,799 | $0 |
| Dr. Michael Sauri, M.d., M.p.h.&T.m, M.D., M.P.H.&T.M | Medical Toxicology | Rockville, MD | $4,244 | $0 |
| Dr. Ryan Carroll, M.d., M.p.h, M.D., M.P.H | Pediatric Critical Care Medicine | Boston, MA | $4,000 | $0 |
Ad
Top Products
- NOVAVAX COVID-19 VACCINE, ADJUVANTED $65.0M
Associated Products (1)
Payment Categories
- Food & Beverage $12,056
- Consulting $300,752
- Travel & Lodging $20,622
- Research $81.3M
About Novavax Inc
Novavax Inc has made $81.7M in payments to 346 healthcare providers, recorded across 6,792 transactions in the CMS Open Payments database. In 2024, the company paid $30.4M. The top product by payment volume is NOVAVAX COVID-19 VACCINE, ADJUVANTED ($65.0M).
Payments were distributed across 43 medical specialties. The top specialty by payment amount is Infectious Disease ($259,917 to 6 doctors).
Payment categories include: Food & Beverage ($12,056), Consulting ($300,752), Research ($81.3M), Travel & Lodging ($20,622).
Novavax Inc is associated with 1 products in the CMS Open Payments database.